Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Archimedes in-licenses Oramorph

Archimedes in-licenses Oramorph

5th August 2008

Archimedes has announced the expansion of its product portfolio with the in-licensing of Oramorph.

The company has reached an agreement with Molteni Farmaceuti to in-licence the commercial rights to the compound in Germany.

Oramorph is a morphine sulphate in a novel liquid formulation to provide immediate release and is approved as a treatment for moderate to severe pain.

The compound is the only orally-administered liquid formulation of immediate release morphine sulphate available in Germany in patient-friendly unit dose vials and offers a simple and convenient treatment option for patients.

It is designed for patients with difficulties swallowing or those who have a large number of tablets to take.

Richard de Souza, chief executive officer of Archimedes, said: “The in-licensing of Oramorph will provide further impetus to our growth overall.”

“It is a high quality product offering real patient and physician benefits.”

He added the company is in a unique position to unlock the commercial potential of the drug, while its marketing of the compound will help the firm build relationships with important prescribers before its launch of NasalFent.

Last month, Archimedes announced it had received funding of 2.77 million euros (2.2 million pounds) from the European Union or the development of an avian influenza vaccine.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.